Quantifying KRAS Protein Levels in CSC-Derived Xenografts
Corresponding Organization :
Other organizations : Boston University, Beth Israel Deaconess Medical Center, Harvard University
Variable analysis
- CSC-derived xenograft tumors from test and control tumors
- KRAS protein expression
- Cytosolic proteins isolated from MDA-MB-231 and Panc1 cell lines
- Equal amounts of cytosolic protein extract (30 µg) used for Western blot analysis
- Cytosolic extracts prepared by tissue homogenization in buffer containing 20 mM Tris-HCl pH 7.4, 1 mM EDTA, 250 mM sucrose, protease inhibitors, followed by centrifugation (11000g x 10 min) and final collection of supernatant (cytosolic fraction)
- Proteins separated on a 15% SDS-PAGE and transferred to PVDF membrane
- Western blot reacted with anti-KRAS and anti-β-actin antibodies
- Immunoreactive proteins detected by chemiluminescence using the ECL Western Detection kit
- Positive control: MDA-MB-231 and Panc1 cell lines
- Negative control: Not explicitly mentioned
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!